Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.008
Neutral
RSI(14)
32.923
Neutral
STOCH(KDJ)(9,3,3)
35.118
Neutral
ATR(14)
0.023
Low Volatility
CCI(14)
-162.605
Sell
Williams %R
76.075
Sell
TRIX(12,20)
-1.342
Sell
StochRSI(14)
50.333
Sell
Search
Calidi Biotherapeutics Inc
CLDIAdd to Watchlist
0.186USD
-0.010-5.21%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
3.58MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Calidi Biotherapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
Calidi Biotherapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 165 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Calidi Biotherapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Calidi Biotherapeutics Inc Highlights
StrengthsRisks
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is developing proprietary allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses (vaccinia virus and adenovirus) and, potentially, other molecules to cancer patients. It is focused on developing two proprietary stem cell-based platforms and one enveloped vaccinia virus platform designed to protect the oncolytic virus, whether natural or engineered, from neutralization by the patient’s immune defenses, allowing for greater infection of the tumor cells and leading to a potential improvement in the antitumor activity of oncolytic viruses over traditional naked oncolytic virus therapies. Its product candidates include the CLD-101 product for high grade glioma (HGG), CLD-101 product for Recurrent HGG, CLD-201 product for solid tumors, CLD-301 (AAA) for multiple indications and CLD-400 (RTNova) for certain lung cancer and metastatic solid tumors.
Fairly Valued
The company’s latest PE is -0.04, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 712.13K shares, increasing 31.33% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.74.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
10.000
Target Price
+4247.83%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Calidi Biotherapeutics Inc is 7.19, ranking 113 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.16
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
Calidi Biotherapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Calidi Biotherapeutics Inc is 7.00, ranking 179 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.04, which is -9776.46% below the recent high of 4.32 and -44211.21% above the recent low of -19.76.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 165/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Calidi Biotherapeutics Inc is 10.00, ranking 1 out of 382 in the Biotechnology & Medical Research industry. The average price target is 10.00, with a high of 10.00 and a low of 10.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
1
analysts
Strong Buy
Current Rating
10.000
Target Price
+4247.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Calidi Biotherapeutics Inc
CLDI
1
CRISPR Therapeutics AG
CRSP
27
Beigene Ltd
ONC
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Calidi Biotherapeutics Inc is 1.20, ranking 377 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 0.26 and the support level at 0.13, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.192
Sell
MA10
0.203
Sell
MA20
0.215
Sell
MA50
0.258
Sell
MA100
0.620
Sell
MA200
1.367
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Calidi Biotherapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 4.68%, representing a quarter-over-quarter increase of 22.08%. The largest institutional shareholder is The Vanguard, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Calidi Biotherapeutics Inc is 2.78, ranking 191 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.35. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
1.33
VaR
--
240-Day Maximum Drawdown
+98.46%
240-Day Volatility
+203.72%
Return
Best Daily Return
60 days
+13.61%
120 days
+13.61%
5 years
--
Worst Daily Return
60 days
-53.14%
120 days
-53.14%
5 years
--
Sharpe Ratio
60 days
-3.40
120 days
-3.49
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+98.46%
3 years
+100.00%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.97
3 years
--
5 years
--
Skewness
240 days
+3.90
3 years
+1.86
5 years
--
Volatility
Realised Volatility
240 days
+203.72%
5 years
--
Standardised True Range
240 days
+189.90%
5 years
--
Downside Risk-Adjusted Return
120 days
-354.04%
240 days
-354.04%
Maximum Daily Upside Volatility
60 days
+141.63%
Maximum Daily Downside Volatility
60 days
+124.65%
Liquidity
Average Turnover Rate
60 days
+143.19%
120 days
+73.59%
5 years
--
Turnover Deviation
20 days
+173.57%
60 days
+6.61%
120 days
-45.21%
Peer Comparison
Biotechnology & Medical Research
Calidi Biotherapeutics Inc
CLDI
5.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
